WHO Experts Plan Bold Steps to Strengthen Global Immunization The World Health Organization’s Strategic Advisory Group of Experts on Immunization (SAGE) has raised significant concerns about mounting pressures that threaten…
Halozyme Announces Positive CHMP Opinion for Bristol Myers Squibb’s Subcutaneous Opdivo® with ENHANZE Halozyme Therapeutics, Inc. (NASDAQ: HALO) recently announced a significant milestone in oncology treatment development, as Bristol Myers…
ACC 2025 Sensydia CPS™ Accurately Assesses Mean Pulmonary Artery Pressure Non-Invasively Sensydia, a clinical-stage company specializing in non-invasive cardiac assessment technologies, has announced promising results from a recent clinical study…
Novotech Secures Investment from GIC, Temasek, and TPG to Drive Global Expansion Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), has announced a significant investment from leading…
FDA Clears Siemens Antithrombin Test as Companion Diagnostic for Qfitlia Siemens Healthineers has announced that its Innovance Antithrombin assay has received FDA clearance for an additional claim, allowing it to…
BMS Gets CHMP Nod for Opdivo-Based Perioperative Regimen in Resectable NSCLC Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
Altasciences Wins 2025 CDMO Leadership Award for Small Molecule Dosage Altasciences, a prominent contract development and manufacturing organization (CDMO), has once again been recognized for its excellence in the pharmaceutical…
Global Cancer Antibody Drug Conjugates Market Report 2024: Industry Growth, Drug Approvals, and Market Expansion The latest report, “Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales &…
Xeris Announces Board Changes Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company dedicated to enhancing patient care through the development and commercialization of innovative therapies, has announced significant changes to…
Vertex Pharmaceuticals Secures UK MHRA Approval for ALYFTREK®, a Next-Generation CFTR Modulator for Cystic Fibrosis Vertex Pharmaceuticals announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency…
Pharma 4.0 Market Report 2025: Projected Growth and Technological Advancements The “Pharma 4.0 – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering, providing an extensive analysis of the…
Merck’s SC Pembrolizumab Shows Noninferior PK to IV KEYTRUDA in Trial Merck, known as MSD outside of the United States and Canada, has presented the first data from the pivotal…